Venus Medtech (Hangzhou) (HKSE:02500) Debt-to-EBITDA : -1.56 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Venus Medtech (Hangzhou)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$541.1 Mil. Venus Medtech (Hangzhou)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$362.6 Mil. Venus Medtech (Hangzhou)'s annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-579.1 Mil. Venus Medtech (Hangzhou)'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.56.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s Debt-to-EBITDA or its related term are showing as below:

HKSE:02500' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.51 Med: -0.35 Max: -0.22
Current: -1.51

During the past 7 years, the highest Debt-to-EBITDA Ratio of Venus Medtech (Hangzhou) was -0.22. The lowest was -1.51. And the median was -0.35.

HKSE:02500's Debt-to-EBITDA is ranked worse than
100% of 437 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs HKSE:02500: -1.51

Venus Medtech (Hangzhou) Debt-to-EBITDA Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Debt-to-EBITDA Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.43

-0.22

-0.90

-1.51

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial							-0.15	-2.81	-0.55	-1.54	-1.56

Competitive Comparison of Venus Medtech (Hangzhou)'s Debt-to-EBITDA

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Medtech (Hangzhou)'s Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Debt-to-EBITDA falls into.

Venus Medtech (Hangzhou) Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Venus Medtech (Hangzhou)'s Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(541.092	+	362.572)	/	-599.213
	=	-1.51

Venus Medtech (Hangzhou)'s annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(541.092	+	362.572)	/	-579.132
	=	-1.56

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Venus Medtech (Hangzhou) (HKSE:02500) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Venus Medtech (Hangzhou) Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines